Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 19 f 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 23f 1 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation of infants and children from 6 weeks up to 5 years of age against invasive disease and acute otitis media caused by streptococcus pneumoniae serotypes 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, and 23f.

Izrael - héber - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of disease caused by streptococcus pneumoniae serotypes 1,3,4,5,6a, 6b, 7f, 9v, 14,18c,19a,19f, 23f (including sepsis, meningitis, bacteraemia, pneumonia and acute otitis media) in infants and children from 2 months to 5 years of age.in adults 50 years of age and older, prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f. this indication is based on immune responses elicited by prevnar 13. there have been no controlled trials in adults demonstrating a decrease in invasive pneumococcal disease or pneumococcal pneumonia after vaccination with prevnar 13.

Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid 30 iu / 0.5 ml; filamentous haemogglutinin (fha) 25 mcg / 0.5 ml - powder and suspension for suspension for injection - tetanus toxoid, combinations with diphtheria toxoid - active immunisation of all infants from the age of 2 months to 7 years of age against diptheria, tetanus, pertussis (dtp) and hib.

Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - salmonela typhi vi polysaccharide 25 mcg / 0.5 ml - solution for injection - typhoid, purified polysaccharide antigen - active immunisation against typhoid fever, for adults and children older than two years of age.

Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - purified hepatitis b antigen - תרחיף להזרקה - purified hepatitis b antigen 20 mcg / 1 ml - hepatitis b, purified antigen - hepatitis b, purified antigen - active immunization against hepatitis b virus.

Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - purified hepatitis b antigen - תרחיף להזרקה - purified hepatitis b antigen 10 mcg / 0.5 ml - hepatitis b, purified antigen - hepatitis b, purified antigen - active immunization against hepatitis b virus infection.

Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 1440 e.l.u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against infections caused by hepatitis a virus.the vaccine is particularly indicated for those at increased risk of infection or transmission.

Izrael - héber - Ministry of Health

droreth ltd - hepatitis a antigen 24 iu / 0.5 ml - solution for injection - hepatitis a, inactivated, whole virus - active immunization against hepatitis a for adults and children age 1 year and above.

Izrael - héber - Ministry of Health

glaxo smith kline (israel) ltd - rabies, inactivated, whole virus - אבקה וממס להכנת תמיסה להזרקה - rabies, inactivated, whole virus 2.5 iu/ml - rabies, inactivated, whole virus - rabies, inactivated, whole virus - active immunization against rabies.

Izrael - héber - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 3 years and over as a booster following primary immunisation . adacel polio is not indicatd for primary immunisation. adacel polio is not indicated for treating diseases caused by b. pertussis, c.diphtheriae or c. tetani or by poliomyelitis infections.